Introduction {#Sec1}
============

Despite major improvements in combatting metastatic melanoma (MM) since the advent of immunotherapy, the overall survival for patients with advanced disease remains low \[[@CR1]\]. To optimize our therapeutic index, as treatment options continue to grow, it is imperative to identify clinical characteristics and/or biomarkers that are predictive of treatment response \[[@CR2]\].

Obesity, defined as a body mass index (BMI) \> 30 kg/m^2^, has conventionally been considered both a poor prognostic factor across most cancer types, and a preventable risk factor for many cancers. Specifically, multiple studies have linked obesity with increased likelihood of developing melanoma and with increased primary tumor thickness, a negative prognostic factor \[[@CR3], [@CR4]\]. More recently, there is a growing number of reports supporting an "obesity paradox," in which patients who are overweight or mildly obese may exhibit a survival benefit, which is overcome at some undefined level of obesity \[[@CR5]--[@CR9]\].

McQuade et al. reported that in a cohort of MM patients, obese male patients treated with immune checkpoint inhibition (ICI) + dacarbazine or targeted therapy exhibited a survival benefit in multivariate analysis, compared to men with a normal BMI \< 25 \[[@CR5]\]. Most provocatively, the results demonstrated a linear relationship that did not reverse in patients with BMI ≥30 kg/m^2^. We believe that this study, and others published since then, have the potential to send a hastily premature message to patients and the oncologic research community of this rather complex relationship.

Methods {#Sec2}
=======

We sought to study the relationship between BMI and progression-free survival (PFS) and overall survival (OS) in a cohort of 423 MM patients receiving ICI, enrolled and prospectively followed-up in the NYU Interdisciplinary Melanoma Cooperative Group database. Stage III and IV MM patients treated with ICI from 2003 to 2018 with known BMI at treatment initiation were classified as normal (\< 25 kg/m^2^), overweight (25--29.9 kg/m^2^), obese (≥30 kg/m^2^). Patients' best response was evaluated according to RECIST criteria, and data were recorded as complete response, partial response, stable disease, and progression of disease. Toxicity data was recorded using the Common Terminology Criteria for Adverse Events according to NIH/NCI guidelines.

Statistical analysis {#Sec3}
--------------------

Baseline patient characteristics in each cohort were compared among the three BMI categories using the Chi square test (Table [1](#Tab1){ref-type="table"}). Median and range of follow up time were calculated in the survivors. Kaplan--Meier curves were generated and compared by the log-rank test to estimate OS and PFS distribution for each BMI group. Using univariate and multivariable cox proportional hazard models, we analyzed the associations between BMI and PFS/OS, stratified by first vs. second or greater-line of ICI treatment. The multivariable analysis adjusted for age, gender, stage, lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group performance status (ECOG PS), number of metastatic sites and BRAF mutation status (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Separate models were performed for each treatment type (anti-CTLA-4, anti-PD-1, combination therapy). Table 1Baseline characteristics of Metastatic Melanoma Patients receiving Immune Checkpoint InhibitorsNormal WeightOverweightObesityPvalueN(%)Total = 423139 (33)165 (39)119 (28)Age (mean(SD))62.1(16)64.5(14)66(13)0.09GenderMale75(54)114(69)78(66)0.02Female64(46)51(31)41(34)StageStage III11(8)14(8)15(13)0.38Stage IV128(92)151(92)104(87)ICI TreatmentCTLA-464(46)75(45)61(51)0.65PD-149(35)55(33)41(34)Combination26(19)35(21)17(14)ECOG Performance Status093(69)120(75)90(80)0.18\>=141(31)40(25)23(20)LDHNormal71(62)97(69)73(79)0.02High44(38)44(31)19(21)BRAF MutationV6007(8)9(8)10(12)0.06Other0(0)5(4)0(0)WT84(92)101(88)74(88)Number of metastatic sites \[mean (SD)\]2.6(1)2.7(1)2.3(1)0.05Line of TRTFirst Line87(63)108(65)77(65)0.87Non-First Line52(37)57(35)42(35)Alive StatusAlive71(51)77(47)59(50)0.74Dead68(49)88(53)60(50)Follow up months \[median (range)\]33.1(1.4-121.1)38.6(2.7-172.2)37.7(11.0-173.3)0.52 Table 2Univariate and Multivariable Cox Proportional Hazard Models of PFS vs BMIanti-CTLA-4anti-PD-1CombinationHR (95% CI)*P* valueHR (95% CI)*P* valueHR (95% CI)*P* valueUnivariate ModelOverweight (vs Normal BMI)1.1(0.67,1.83)0.71.58(0.78,3.19)0.210.36(0.15,0.85)0.02Obesity (vs Normal BMI)0.98(0.59,1.63)0.931.49(0.71,3.13)0.30.17(0.04,0.65)0.01Multivariable ModelOverweight (vs Normal BMI)0.97(0.56,1.69)0.922.34(1.05,5.2)0.040.5(0.15,1.71)0.27Obesity (vs Normal BMI)1.16(0.7,1.94)0.572.46(1.03,5.89)0.040.18(0.05,0.74)0.02Female0.94(0.59,1.51)0.811.05(0.6,1.84)0.851.8(0.72,4.49)0.21Age at Treatment Initiation1(0.98,1.01)0.770.99(0.97,1.01)0.280.99(0.95,1.03)0.67Stage IV at Treatment Initiation(vs Stage III)3(1.07,8.41)0.040.88(0.3,2.64)0.820.19(0.02,1.62)0.13ECOG Status1.78(1.22,2.6)0.0032.67(1.65,4.31)0.0033.02(1.44,6.32)\<.001LDH High1.16(0.74,1.82)0.522.25(1.08,4.7)0.031.45(0.65,3.23)0.36Number of Metastatic Sites1.21(1.04,1.4)0.021.11(0.91,1.36)0.290.94(0.7,1.25)0.68BRAF Mutated0.86(0.37,2)0.730.43(0.12,1.6)0.211.83(0.61,5.54)0.28 Table 3Univariate and Multivariable Cox Proportional Hazard Models of OS vs BMIanti-CTLA-4anti-PD-1CombinationHR (95% CI)*P* valueHR (95% CI)*P* valueHR (95% CI)*P* valueUnivariate ModelOverweight (vs Normal BMI)1.05(0.61,1.8)0.861.29(0.7,2.36)0.420.69(0.29,1.62)0.39Obesity (vs Normal BMI)1.07(0.63,1.8)0.810.88(0.42,1.85)0.740.57(0.19,1.73)0.32Multivariable ModelOverweight (vs Normal BMI)0.83(0.47,1.47)0.521.6(0.86,2.96)0.140.7(0.2,2.47)0.58Obesity (vs Normal BMI)1.22(0.75,2)0.421.04(0.48,2.24)0.920.92(0.24,3.49)0.9Female0.73(0.45,1.18)0.190.43(0.24,0.78)0.011.18(0.48,2.92)0.72Age at Treatment Initiation1.01(0.99,1.02)0.21.01(0.98,1.03)0.611.01(0.98,1.04)0.66Stage IV at Treatment Initiation(vs Stage III)15.76(2.12,117.24)0.011.07(0.38,2.98)0.91.12(0.1,12.97)0.93ECOG Status2.23(1.62,3.07)\<.0012.92(1.88,4.51)\<.0012.45(1.47,4.1)0.001LDH High1.62(1.05,2.5)0.032.35(1.27,4.35)0.012.48(0.9,6.85)0.08Number of Metastatic Sites1.2(1,1.44)0.061.16(0.97,1.38)0.10.85(0.58,1.24)0.4BRAF Mutated0.99(0.53,1.85)0.960.78(0.25,2.48)0.680.78(0.19,3.16)0.73

As an exploratory analysis, we further examined the association between the change in BMIs with the changes in patients' responses and toxicity in the subset of MM patients who received multiple lines of ICI treatments. We first classified them as patients with constant, increased and decreased BMIs derived from the BMI classifications at the time of their later and earlier ICI treatment initiations. For patients with more than two lines of treatments, the last and first treatment lines were used. We then assessed their changes in ECOG PS, number of metastatic sites, best response and toxicity similarly between the lines of ICI treatments. We then used Fisher's Exact Tests to assess the association between the change in BMIs with the changes in patients' responses and toxicity.

Results {#Sec4}
=======

As seen in Table [1](#Tab1){ref-type="table"}, our cohort of 423 MM patients receiving ICI contained 139 (33%) patients with normal BMI; 165 (39%) patients with overweight BMI and 119 (28%) patients with obese BMI with a median follow up time of 36.3 months (1.4--173.3) since ICI treatment initiation. Three hundred forty-two (81%) patients in our cohort received treatment as part of standard of care, and the remaining patients were enrolled in a clinical trial. The baseline characteristics and follow up time of the MM cohort are distributed equally among patients in the three BMI classifications.

Our MM patients treated with ICI who were overweight or obese did not have different PFS than patients with normal BMI, as seen in Fig. [1](#Fig1){ref-type="fig"} (*P* = 0.75). Stratifying this cohort by first vs. non-first line ICI revealed a moderate but insignificant association between being overweight or obese and better PFS in patients who received first line ICI (*P* = 0.17). Conversely, an association with worse PFS was observed in patients who received non-first line ICI (*P* = 0.51). Figure [2](#Fig2){ref-type="fig"} shows there was no OS benefit seen in patients that were overweight or obese (*P* = 0.75). Again, stratification by first vs. non-first line ICI showed a mild, yet insignificant association between overweight or obese BMI classifications and survival in first line ICI (*P* = 0.47), but it was reversed in the non-first line cohort (*P* = 0.42). Fig. 1Progression-free survival by BMI shows heterogeneous trends when stratifying by clinical features. Progression-free survival in (**a**) the entire MM cohort, **b** the MM patients who received first-line ICI, **c** the MM patients who received non-first-line ICI, **d** the MM patients who received anti-CTLA4 treatment, **e** the MM who received anti-PD1 treatment, and (**f**) the MM patients who received combination treatment. All *p*-values are from the log-rank tests Fig. 2Overall survival by BMI shows no association between neither overweight nor obese classification. Overall survival in (**a**) the entire MM cohort, **b** the MM patients who received first-line ICI, **c** the MM patients who received non-first-line ICI, **d** the MM patients who received anti-CTLA4 treatment, **e** the MM who received anti-PD1 treatment, and **f** the MM patients who received combination treatment. All p-values are from the log-rank tests

In a univariate analysis, overweight and obese patients receiving combination ICI had a statistically significant PFS benefit (HR = 0.36 \[0·15--0.85\]), *P* = 0.02 and HR = 0.17 \[0.04--0.65, *P* = 0.01 for overweight and obesity groups respectively), whereas patients receiving the other treatment types showed heterogeneous trends (P interaction = .005). In the multivariable analysis, this significance held for obese patients (*P* = 0.02), but was lost in the overweight category (*P* = 0.27). In both univariate and multivariable analysis, no association was seen between increased BMI and OS in any ICI treatment (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). To examine robustness, we also performed univariate and multivariable models with all patients, stratified by treatment groups. There was no significant association between BMI and PFS or OS (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Figures [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"} reveal a positive association of BMI with best response and with higher rate of immune related adverse events. These associations, however, are not statistically significant. Fig. 3Best response is insignificantly associated with higher BMI. Best response percentages stratified by Normal Weight, Overweight, and Obesity Fig. 4Toxicity is insignificantly associated with higher BMI. Immune-related adverse events stratified by Normal Weight, Overweight, and Obesity

Table [4](#Tab4){ref-type="table"} illustrates that 104 patients received multiple ICI treatment lines in our cohort. Of these patients, 86 (83%) patients remained constant in their BMI classifications, while 14 (13%) patients decreased from a higher to a lower BMI classification and 4 (4%) patients increased from a lower to higher BMI classification between multiple treatments. Decreases in BMI classification showed a trend of association with increases in ECOG PS and number of metastatic sites compared with patients with constant and increased BMIs. Interestingly, the four patients with increased BMIs during treatments showed higher percentages of deteriorating response categories (2/4) and decreased toxicities (3/4). Due to low sample numbers of patients who changed BMI categories during individual treatments, these results were insignificant and warrant further examination in larger cohorts. Table 4Association between BMI classification change and response/toxicity changes in patients receiving multipleChange in BMI ClassificationHigher to lowerConstantLower to Higher*P* valueN(%)Total = 10414(13)86(83)4(4%)Change in ECOG Performance StatusDecrease PS1(7)3(3)0(0)0.41Constant PS7(50)61(71)3(75)Increase PS6(43)22(26)1(25)Change in Number of metastatic sitesDecrease \# of sites1(7)10(12)2(50)0.23Constant \# of sites4(29)35(41)1(25)Increase \# of sites9(64)41(48)1(25)Change in ResponseImproved OR5(36)30(35)1(25)0.08Constant OR8(57)24(28)1(25)Decrease OR1(7)32(37)2(50)Change in ToxicityDecrease Toxicity4(29)16(19)3(75)0.14Constant Toxicity5(36)37(43)0(0)Increase Toxicity5(36)33(38)1(25)

Discussion {#Sec5}
==========

Our results, which showed heterogeneous trends when accounting for key clinical features, demonstrate the seemingly complex relationship between BMI and response to ICI. We caution the scientific community to consider several important points prior to drawing conclusions that could potentially influence patient guidance.

First, preclinical data strongly support the association between obesity and aggressive tumor biology across multiple species. Recent genetic and metabolic analyses of diet-induced obese mice bearing human B16 melanoma tumors demonstrated increased ulceration, tumor progression and invasion, and increased levels of PD-1 expression. In addition, analyses of publically available expression data cemented the association between obesity an immunosuppressed phenotype \[[@CR6]\]. Patients with high BMIs are more likely to have chronic inflammation, which is associated with a decrease in M2 macrophages, CD8 T cells, and natural killer T cells \[[@CR10]\]. Given these analyses, the mechanistic understanding to explain a possible survival benefit for obese patients receiving ICI is unclear. Future investigations should address baseline inflammation levels as well as sarcopenic vs. normal-weight obesity to better elucidate this mechanism.

Second, the pharmacokinetic characteristics of monoclonal antibody absorption, distribution, and clearance differ greatly from those of traditional small molecule drugs, as renal and biliary excretion is negligible \[[@CR11]\]. Thus, mostly the liver must metabolize therapeutic antibodies prior to clearance. Obesity is associated with disturbances in metabolism via enhanced adipose secretion of free fatty acids and proinflammatory cytokines, which affect circulatory and hepatic functions \[[@CR10], [@CR11]\]. Further, studies have shown that body weight specifically influences the clearance and volume of distribution of therapeutic antibodies \[[@CR11]--[@CR13]\]. Given that dosing of ICI as weight-based vs. fixed has varied over time, across treatment types, and between institutions, the absence of pharmacokinetic control in analyzing the relationship between BMI and ICI represents another limitation in the generalizability of the results from this and prior studies. We hypothesize that there are underlying metabolic mechanisms that drive the observed positive association between BMI and response to ICI. To that end, metabolic profiles, created by combining host genomics, baseline inflammation and serum creatinine levels as indicators of adiposity, and tumor microenvironment features, may provide a more scientifically rational biomarker for response than BMI.

Finally, clinical data in support of a survival benefit are irreproducible amongst different investigations. Wang et al. and Naik et al. showed a significantly positive association between BMI and survival in melanoma patients treated with anti-PD1 ICI, McQuade et al. and Richtig et al. showed this positive association in patients treated with anti-CTLA4, and here we show the association in patients treated with combination anti-CTLA4 + anti-PD1 therapy \[[@CR5], [@CR6], [@CR8], [@CR9]\]. Notably, several investigations did not find the association in all treatment types analyzed in their studies. We acknowledge that the numerous positive reports suggest that BMI does influence response to ICI, but each of these studies utilized different covariates in their analyses as well as distinct statistical models to assess the associations. Furthermore, our cohort and other studied cohorts include patients treated as part of a clinical trial and as standard of care, which have different patient characteristics and outcomes due to inclusion criteria for clinical trials. These distinctions likely contribute additional complexity to the relationship. Moreover, an analysis of outcomes of 945 patients enrolled in phase III clinical trials demonstrated that the combination therapy had higher rates of PFS and OS than single-agent therapy in patients with BRAF mutations, stage M1c disease, and elevated LDH \[[@CR14]\]. It is possible that our study is biased towards the null hypotheses due to lack of power or possible secular trends in melanoma diagnosis and ICI treatment effects in the prolonged study period \[[@CR15]\]. This highlights the significance of systematically accounting for overall disease burden in the context of these and other variables while analyzing the association of BMI and response to ICI.

Several investigations have not reproducibly and comprehensively considered clinical confounders, such as genetic mutations, PD-L1 positivity, time-period of therapy and overall disease burden, which limits the ability to draw accurate conclusions about the relationship between BMI and response to ICI. When stratified by key clinical features including gender, treatment type, treatment line, tumor type, and BMI classification changes, our study and others have showed discordant results, and even reversal of trends. The varied designs and results amongst numerous studies highlight the need for a thorough investigation, on a significantly larger scale, to truly elucidate BMI's impact on clinical outcomes in cancer. The scientific community must also pause to consider the known detrimental health effects of obesity, including hypertension, diabetes, and risk of cardiovascular disease when counseling patients that are treated with ICI \[[@CR16], [@CR17]\]. We believe it is of crucial importance to apply the same or higher level of scientific rigor to identifying an established negative health characteristic, such as high BMI, as a potential biomarker for a positive clinical outcome as the community applies to other biomarkers with limited preclinical data. Using previous publications to support original discoveries is central to the scientific method, but has the potential to over-emphasize perceived associations in cohort studies if numerous publications begin to cite inconclusive results.

Additional file
===============

 {#Sec6}

Additional file 1:Univariate and multivariable analyses of all patients in study, not stratified by treatment type, demonstrate no significant association between BMI and PFS or OS. (PDF 9 kb)
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:   Body mass index
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:   Eastern Cooperative Oncology Group performance status
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:   Immune checkpoint inhibition
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:   Overall survival
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:   Progression-free survival
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